+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncolytic Virus Therapies Market by Cancer Indication (Glioblastoma, Head And Neck Cancer, Melanoma), Virus Type (Genetically Modified Virus, Wild Type Virus), Administration Route, End User - Global Forecast 2025-2030- Product Image
Oncolytic Virus Therapies Market by Cancer Indication (Glioblastoma, Head And Neck Cancer, Melanoma), Virus Type (Genetically Modified Virus, Wild Type Virus), Administration Route, End User - Global Forecast 2025-2030- Product Image
Sale

Oncolytic Virus Therapies Market by Cancer Indication (Glioblastoma, Head And Neck Cancer, Melanoma), Virus Type (Genetically Modified Virus, Wild Type Virus), Administration Route, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5925124
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Oncolytic virus therapies are rapidly reshaping the oncology landscape by offering targeted tumor destruction combined with immune system activation. Senior decision-makers evaluating strategic investment opportunities in advanced therapeutic modalities will find this comprehensive report on the oncolytic virus therapies market critical for informed decision-making.

Market Snapshot: Strong Growth and Expanding Opportunities in Oncolytic Virus Therapies

The Oncolytic Virus Therapies Market grew from USD 132.50 million in 2024 to USD 153.79 million in 2025 and is projected to continue advancing at a CAGR of 15.93%, reaching USD 321.81 million by 2030. This growth reflects ongoing progress in virology, immunology, and genetic engineering, with an increasing number of late-stage clinical trials and a maturing commercial pipeline. Rising demand for precision oncology solutions and combination regimens positions oncolytic virus therapies as a transformative segment within cancer care.

Scope & Segmentation: Comprehensive Insight into Market Structure and Dynamics

  • Cancer Indications: Glioblastoma, Head and Neck Cancer, Melanoma
  • Virus Types: Genetically Modified Viruses (Adenovirus, Herpes Simplex Virus, Vaccinia Virus), Wild Type Viruses
  • Administration Routes: Intratumoral, Intravenous
  • End Users: Hospitals, Research Institutes, Specialty Clinics
  • Geographies: Americas (including United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Players: Amgen Inc., Merck & Co., Inc., Replimune Group, Inc., Oncolytics Biotech Inc., Sorrento Therapeutics, Inc., Transgene SA, PsiOxus Therapeutics Ltd, OncoSec Medical Incorporated, Targovax ASA, SillaJen, Inc.

Key Takeaways for Strategic Decision-Makers

  • Oncolytic virus therapies combine targeted cell destruction with immune activation, supporting differentiation from traditional chemotherapies and radiotherapies.
  • Strategic integrations of immunomodulatory genes and customized viral backbones are enabling therapies with heightened selectivity and improved tolerance profiles.
  • Dual and combination regimens, particularly in conjunction with immunotherapies, are demonstrating increased efficacy in solid and metastatic tumors.
  • Manufacturing process innovations are enhancing scalability and accelerating readiness for late-stage clinical development, which is vital for rapid market expansion.
  • Emerging regional hubs, especially within Asia-Pacific and select EMEA markets, are starting to shape innovation and investment patterns across the sector.

Tariff Impact: Navigating Supply Chain and Cost Dynamics

The imposition of new United States tariffs in 2025 is introducing higher duties on raw materials and viral vector components, leading to increased production costs and supply chain uncertainties. Biopharmaceutical companies are responding by diversifying suppliers and establishing regional manufacturing hubs to mitigate risk and protect research continuity. These measures are transforming procurement strategies and underlining the importance of robust logistics planning amid global trade fluctuations.

Methodology & Data Sources

This report employs a rigorous methodology that blends systematic secondary analysis with targeted expert interviews. Peer-reviewed literature, clinical trial records, company statements, and primary stakeholder insights have been thoroughly analyzed to validate trends, segment performance, and developmental milestones in the oncolytic virus therapies market.

Why This Report Matters

  • Enables executive teams to prioritize resources by clearly mapping innovation hotspots and emerging commercial models across key territories.
  • Delivers actionable guidance for navigating regulatory, supply chain, and competitive environments unique to oncolytic virus therapies.
  • Supports multi-disciplinary strategy formulation by aligning clinical, operational, and market access considerations.

Conclusion

Oncolytic virus therapies stand at the intersection of scientific advancement and evolving market demands. This report offers critical intelligence to guide senior leaders in strategic planning, risk mitigation, and opportunity capture in this dynamic field.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in arming oncolytic viruses with bispecific antibodies and cytokine payloads for enhanced tumor immune activation
5.2. Integration of synthetic biology techniques for controllable replication and tumor-specific lysis in oncolytic virus design
5.3. Clinical trial successes combining oncolytic viruses with PD-1 checkpoint inhibitors to improve response rates in solid tumors
5.4. Development of systemic delivery platforms and nanoformulations to overcome neutralizing antibodies in oncolytic virotherapy
5.5. Adoption of biomarker-driven patient selection strategies using tumor molecular profiling to optimize oncolytic virus efficacy
5.6. Regulatory pathway harmonization efforts and expedited approval programs accelerating oncolytic viral therapy commercialization
5.7. Collaborative partnerships between biotech companies and academic centers to advance personalized oncolytic virus platforms based on tumor antigen repertoires
5.8. Manufacturing scale-up innovations leveraging continuous bioprocessing for cost-effective production of clinical-grade oncolytic viruses
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Oncolytic Virus Therapies Market, by Cancer Indication
8.1. Introduction
8.2. Glioblastoma
8.3. Head And Neck Cancer
8.4. Melanoma
9. Oncolytic Virus Therapies Market, by Virus Type
9.1. Introduction
9.2. Genetically Modified Virus
9.2.1. Adenovirus
9.2.2. Herpes Simplex Virus
9.2.3. Vaccinia Virus
9.3. Wild Type Virus
10. Oncolytic Virus Therapies Market, by Administration Route
10.1. Introduction
10.2. Intratumoral
10.3. Intravenous
11. Oncolytic Virus Therapies Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Research Institutes
11.4. Specialty Clinics
12. Americas Oncolytic Virus Therapies Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Oncolytic Virus Therapies Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Oncolytic Virus Therapies Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Amgen Inc.
15.3.2. Merck & Co., Inc.
15.3.3. Replimune Group, Inc.
15.3.4. Oncolytics Biotech Inc.
15.3.5. Sorrento Therapeutics, Inc.
15.3.6. Transgene SA
15.3.7. PsiOxus Therapeutics Ltd
15.3.8. OncoSec Medical Incorporated
15.3.9. Targovax ASA
15.3.10. SillaJen, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ONCOLYTIC VIRUS THERAPIES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. ONCOLYTIC VIRUS THERAPIES MARKET: RESEARCHAI
FIGURE 24. ONCOLYTIC VIRUS THERAPIES MARKET: RESEARCHSTATISTICS
FIGURE 25. ONCOLYTIC VIRUS THERAPIES MARKET: RESEARCHCONTACTS
FIGURE 26. ONCOLYTIC VIRUS THERAPIES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ONCOLYTIC VIRUS THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY WILD TYPE VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRATUMORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 70. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 71. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 72. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 73. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 74. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 75. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 76. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 77. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 80. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 81. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 82. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 83. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 84. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 85. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 86. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 87. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 132. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 133. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 134. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 135. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 136. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 137. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 138. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 139. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 142. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 143. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 144. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 145. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 146. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 147. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 148. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 149. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 162. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 163. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 164. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 165. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 166. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 167. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 168. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 169. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 172. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 173. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 174. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 175. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 176. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 177. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 178. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 179. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 180. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 212. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 213. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 214. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 215. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 216. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 217. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 218. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 219. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 232. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 233. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 234. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 235. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 236. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 237. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 238. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 239. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 242. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 243. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 244. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 245. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 246. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 247. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 248. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 249. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 272. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 273. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 274. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 275. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 276. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 277. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 278. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 279. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 282. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 283. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 284. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 285. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 286. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 287. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 288. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 289. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 292. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 296. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 299. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 302. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 303. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 304. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2025-2030 (USD MILLION)
TABLE 305. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2018-2024 (USD MILLION)
TABLE 306. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY MODIFIED VIRUS, 2025-2030 (USD MILLION)
TABLE 307. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 308. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 309. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
TABLE 312. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
TABLE 313. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2024 (USD MILLION)
TABLE 314. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Oncolytic Virus Therapies market report include:
  • Amgen Inc.
  • Merck & Co., Inc.
  • Replimune Group, Inc.
  • Oncolytics Biotech Inc.
  • Sorrento Therapeutics, Inc.
  • Transgene SA
  • PsiOxus Therapeutics Ltd
  • OncoSec Medical Incorporated
  • Targovax ASA
  • SillaJen, Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 153.79 Million
Forecasted Market Value ( USD ) by 2030 $ 321.81 Million
Compound Annual Growth Rate15.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Oncolytic Virus Cancer Therapy Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Oncolytic Virus Cancer Therapy Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Oncolytic Virus Therapies Market Report by Virus Type, Application, End Use, and Region 2025-2033 - Product Image

Oncolytic Virus Therapies Market Report by Virus Type, Application, End Use, and Region 2025-2033

  • Report
  • 133 Pages
  • Global
From
Oncolytic Virus Therapy Market Report 2025 - Product Image

Oncolytic Virus Therapy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Oncolytic Virus Cancer Therapy Pipeline Analysis Report 2025 - Product Image

Oncolytic Virus Cancer Therapy Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Oncolytic Virus Immunotherapy - Global Strategic Business Report - Product Image

Oncolytic Virus Immunotherapy - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From

About the Oncolytic Virus Drug Market

The Oncolytic Virus Drug market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Oncolytic virus drugs are a type of biologic therapy that uses viruses to target and destroy cancer cells. These drugs are designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. They can be used alone or in combination with other treatments such as chemotherapy or radiation therapy. Oncolytic virus drugs have the potential to improve the efficacy of existing treatments and reduce the side effects associated with them. Some companies in the Oncolytic Virus Drug market include Amgen, Merck, Pfizer, and Novartis. These companies are actively researching and developing new oncolytic virus drugs to treat a variety of cancers. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.